- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05678257
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer
This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with unresectable metastatic colorectal cancer.
A total of 171 patients will be randomized 1:1:1 to either NUFIRI-bev on a weekly NUC-3373 schedule, NUFIRI-bev based on an alternate weekly NUC-3373 schedule, or FOLFIRI bev on an alternate weekly schedule. The main objectives are to assess and compare the efficacy and safety of the 3 regimens. Pharmacokinetics will be assessed on the 2 NUFIRI arms.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: NuTide:323 Project Manager
- Phone Number: +44 (0)357 1111
- Email: NuTide323@nucana.com
Study Locations
-
-
-
Nantes, France, 44000
- Centre Hospitalier UniversitaireNantes - Hôtel Dieu
-
-
Alsace
-
Strasbourg, Alsace, France, 67000
- Strasbourg Oncology Liberale - Clinique Sainte-Anne
-
-
Bouches-du-Rhône
-
Marseille, Bouches-du-Rhône, France, 13003
- Hôpital Européen Marseille
-
-
Bourgogne-Franche-Comté
-
Dijon, Bourgogne-Franche-Comté, France, 21079
- Centre Georges-François Leclerc
-
-
Doubs
-
Besançon, Doubs, France, 25000
- Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz
-
-
Gironde
-
Bordeaux, Gironde, France, 33076
- Institut Bergonie
-
-
Vienne
-
Poitiers, Vienne, France, 86000
- Centre Hospitalier Universitaire de Poitiers
-
-
Île-de-France
-
Paris, Île-de-France, France, 75015
- Hopital Europeen Georges-Pompidou
-
Suresnes, Île-de-France, France, 92150
- Hopital Foch
-
-
-
-
-
Berlin, Germany, 13353
- Charité Campus Virchow-Klinikum
-
-
Bavaria
-
München, Bavaria, Germany, 81737
- München Klinik Neuperlach
-
-
Hesse
-
Frankfurt, Hesse, Germany, 60488
- Krankenhaus Nordwest
-
-
Tübingen
-
Ulm, Tübingen, Germany, 89081
- Universitätsklinik Ulm - Oberen Eselsberg
-
-
-
-
-
Ancona, Italy, 60126
- Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
-
Milano, Italy, 20162
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
-
Potenza, Italy, 85100
- Azienda Ospedaliera Regionale San Carlo
-
-
Campania
-
Napoli, Campania, Italy, 80131
- Azienda Ospedaliera Universitaria - Università degli Studi della Campania Luigi Vanvitelli
-
-
Lombardia
-
Milano, Lombardia, Italy, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
-
Ravenna
-
Faenza, Ravenna, Italy, 48121
- Ospedale Santa Maria delle Croci di Ravenna
-
-
Toscana
-
Firenze, Toscana, Italy, 50134
- Azienda Ospedaliero Universitaria Careggi
-
-
Veneto
-
Padova, Veneto, Italy, 35128
- Istituto Oncologico Veneto - IRCCS
-
-
-
-
-
Barcelona, Spain, 8035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spain, 08041
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Spain, 8908
- Hospital Duran I Reynals
-
León, Spain, 24008
- Hospital de Leon
-
Lleida, Spain, 25198
- Hospital Universitari Arnau de Vilanova
-
Madrid, Spain, 28041
- Hospital Universitario 12 De Octubre
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
Madrid, Spain, 28033
- MD Anderson Cancer Center Madrid
-
Málaga, Spain, 29010
- Hospital Universitario Virgen de la Victoria
-
Sevilla, Spain, 41013
- Hospital Universitario Virgen del Rocío
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Institut Català d'Oncologia - ICO Badalona - Hospital Universitari Germans Trias i Pujol
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Spain, 15706
- Complejo Hospitalario Universitario de Santiago (CHUS)
-
-
Madrid
-
Alcorcón, Madrid, Spain, 28922
- Hospital Universitario Fundacion Alcorcon
-
Majadahonda, Madrid, Spain, 28222
- Hospital Universitario Puerta de Hierro
-
-
-
-
-
Cardiff, United Kingdom, CF14 2TL
- Velindre University NHS Trust
-
Glasgow, United Kingdom, G51 4TF
- NHS Greater Glasgow and Clyde
-
-
Essex
-
Romford, Essex, United Kingdom, RM7 OAG
- Queen's Hospital
-
-
Greater London
-
London, Greater London, United Kingdom, NW3 2QG
- Royal Free London NHS Foundation Trust
-
London, Greater London, United Kingdom, NW1 2PG
- University College London Hospitals NHS Foundation Trust
-
London, Greater London, United Kingdom, SE1 9RT
- Guy's and Saint Thomas' NHS Foundation Trust
-
-
Lancashire
-
Manchester, Lancashire, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust
-
-
Middlesex
-
Northwood, Middlesex, United Kingdom, HA6 2RN
- Mount Vernon Cancer Centre - East and North Hertfordshire NHS Trust
-
-
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Helen F. Graham Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University Medical Center
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida Health Medical Oncology - Davis Cancer Pavilion
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Norton Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts Worcester
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Morristown Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Dallas, Texas, United States, 75246
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
-
Tyler, Texas, United States, 75702
- USOR - Texas Oncology Northeast Texas
-
-
Washington
-
Kirkland, Washington, United States, 98034
- Fred Hutchinson Cancer Center at Evergreen Health
-
Vancouver, Washington, United States, 98684
- Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of written informed consent.
- Histological or cytological confirmation of colorectal adenocarcinoma (excluding appendiceal and anal canal cancers, as well as signet-ring cell carcinoma) that is unresectable and metastatic.
- Measurable disease (as defined by RECIST v1.1).
- Received ≥2 months of a first-line fluoropyrimidine and oxaliplatin-containing regimen for metastatic disease or relapsed within 6 months of completing a fluoropyrimidine and oxaliplatin-containing neoadjuvant/adjuvant therapy. Previous treatment with standard of care chemotherapy regimens in combination with molecular targeted therapies (e.g., VEGF and EGFR pathway inhibitors and immuno-oncology agents) is permitted. Previous treatment with maintenance therapy (e.g., capecitabine) is also allowed. Patients who started on a fluoropyrimidine and oxaliplatin-containing regimen in any setting but must discontinue the oxaliplatin due to.toxicity or allergy (and are now unable to receive oxaliplatin) are considered eligible regardless of the number of cycles of oxaliplatin they received.
- Known RAS and BRAF status. Patients with wild-type RAS tumours must have received prior treatment with an EGFR inhibitor, unless this was not standard of care according to relevant region-specific treatment recommendations.
- Known UGT1A1 status, or patient consents to UGT1A1 status testing if unknown.
- Known DPD activity status, or patient consents to DPD status testing if unknown. See exclusion criterion 1.
- Age ≥18 years.
- Minimum life expectancy of ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1.
- Adequate bone marrow function as defined by: absolute neutrophil count (ANC) ≥1.5 × 109/L, platelet count ≥100 × 109/L, and haemoglobin ≥9 g/dL. Patients with benign neutropenia may be discussed on a case-by-case basis with the medical monitor.
- Adequate liver function, as defined by: serum total bilirubin ≤1.5 × ULN), AST and ALT ≤2.5 × ULN (or ≤5 × ULN if liver metastases are present).
- Adequate renal function assessed as serum creatinine <1.5 × ULN and glomerular filtration rate ≥50 mL/min (calculated by the Cockcroft-Gault method).
- Serum albumin ≥3 g/dL.
- Ability to comply with protocol requirements.
- Female patients of child-bearing potential must have a negative serum pregnancy test within 7 days prior to the first study drug administration. This criterion does not apply to patients who have had a previous hysterectomy or bilateral oophorectomy. Male patients and female patients of child-bearing potential must agree to practice true abstinence (defined in Section 10.3.1) or to use two forms of contraception, one of which must be highly effective. These forms of contraception must be used from the time of signing consent, throughout the treatment period, and for 6 months following the last dose of any study medication. Oral or injectable contraceptive agents cannot be the sole method of contraception
- Patients must have been advised to take measures to avoid or minimize exposure of the skin and eyes to UV light, including avoiding sunbathing and solarium use, for the duration of study participation and for a period of 4 weeks following the last dose of study medication
Exclusion Criteria:
- History of hypersensitivity or current contra-indications to 5-FU, FUDR, or capecitabine.
- History of hypersensitivity or current contra-indication to any of the combination agents required for the study.
- History of allergic reactions attributed to components of the NUC-3373 drug product formulation.
- History of hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies.
- History of or known central nervous system or leptomeningeal metastases.
- Symptomatic ascites, ascites currently requiring drainage procedures or ascites requiring drainage over the prior 3 months.
- Mutant BRAF V600E status.
- MSI high or dMMR.
- Prior treatment with irinotecan.
- Chemotherapy, hormonal therapy, radiotherapy (other than a short cycle of palliative radiotherapy [e.g., for bone pain]*), immunotherapy, biological agents, or exposure to another investigational agent within 21 days (or four times the half-life for molecular targeted agents, whichever is shorter) of first administration of study treatment:
- Residual toxicities from prior chemotherapy or radiotherapy which have not regressed to Grade ≤1 severity (CTCAE v5.0), except for alopecia and residual Grade 2 neuropathy.
- History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, surgically excised or potentially curatively treated ductal carcinoma in situ of the breast, or low-grade prostate cancer or patients after prostatectomy. Patients with previous invasive cancers are eligible if treatment was completed >3 years prior to initiating the current study treatment, and the patient has had no evidence or recurrence since then.
- Presence of an active bacterial or viral infection (including SARS-CoV-2, Herpes Zoster, Varicella Zoster or chickenpox), known Human Immunodeficiency Virus (HIV) positive or known active hepatitis B or C.
- Presence of any uncontrolled concurrent serious illness, medical condition or other medical history, including laboratory results, which, in the Investigator's opinion, would be likely to interfere with the patient's ability to participate in the study or with the interpretation of the results (refer to protocol for further details).
- Any condition that, in the judgment of the Investigator, may affect the patient's ability to provide informed consent and undergo study procedures.
- Patients with a history of haemoptysis (1/2 teaspoon or more of red blood) within 6 months prior to enrolment.
- Wound healing complications or surgery within 28 days of starting bevacizumab (wound healing must have been fully completed before starting bevacizumab). Investigators may allow patients to initiate treatment with the other study drugs (i.e., NUC-3373/5-FU, LV and irinotecan) on C1D1 but withhold bevacizumab for at least 15 days, but no longer than 28 days, to allow completion of wound healing in patients who would otherwise be eligible for the study, in line with standard local practice and after discussion with the Medical Monitor. Patients who have not received bevacizumab by C2D1 must be replaced.
- Unhealed wound, active gastric or duodenal ulcer, or bone fracture.
- Serious thromboembolic event in the 6 months before inclusion.
- Patients with a history of haemorrhage within 6 months prior to enrolment.
- Known inherited or acquired bleeding disorders.
- Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of packed RBC transfusions during the 4-week period prior to screening.
- Uncontrolled hypertension.
- Severe proteinuria or nephrotic syndrome.
- Acute intestinal obstruction or sub-obstruction, history of inflammatory intestinal disease or extended resection of the small intestine. Presence of a colic prosthesis.
- History of abdominal fistulas, trachea-oesophageal fistulas, any other Grade 4 gastrointestinal perforations, non-gastrointestinal fistulas, or intra-abdominal abscesses 6 months prior to screening.
- Currently pregnant, lactating or breastfeeding.
- Required concomitant use of brivudine, sorivudine and analogues.
- Required concomitant use of St John's Wort.
- Required concomitant use of drugs known to prolong QT/QTc interval.
- Required concomitant use of strong CYP3A4 inducers or strong CYP3A4 inhibitors. The use of strong CYP3A4 inducers within 2 weeks of first receipt of study drug or the use of strong CYP3A4 inhibitors within 1 week of first receipt of study drug is also excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NUFIRI-bev on a Q1W NUC-3373 schedule
Arm A: Study treatment will be administered in 28-day cycles as follows:
|
Intravenous infusion
Other Names:
Intravenous infusion
Other Names:
Intravenous infusion
Other Names:
Intravenous infusion
Other Names:
|
Experimental: NUFIRI-bev on a Q2W NUC-3373 schedule
Arm B: Study treatment will be administered in 28-day cycles as follows:
|
Intravenous infusion
Other Names:
Intravenous infusion
Other Names:
Intravenous infusion
Other Names:
Intravenous infusion
Other Names:
|
Active Comparator: FOLFIRI-bev on a Q2W schedule
Arm C: Study treatment will be administered in 28-day cycles as follows:
|
Intravenous infusion
Other Names:
Intravenous infusion
Other Names:
Intravenous infusion
Other Names:
Intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients achieving progress-free survival (PFS)
Time Frame: Assessed from baseline to 30 days after last dose of study drug
|
PFS assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, defined as the time from randomisation to the first observation of objective tumour progression or death from any cause
|
Assessed from baseline to 30 days after last dose of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients achieving a reduction in tumour volume
Time Frame: Assessed from baseline to 30 days after last dose of study drug
|
Objective response rate, defined as the percentage of patients achieving a complete or partial (30%+) response to treatment
|
Assessed from baseline to 30 days after last dose of study drug
|
Number of patients surviving
Time Frame: Assessed from baseline to 30 days after last dose of study drug
|
Overall survival, defined as the time from randomization to the time of death from any cause
|
Assessed from baseline to 30 days after last dose of study drug
|
Number of patients reporting treatment-emergent adverse events (TEAEs)
Time Frame: Assessed from baseline to 30 days after last dose of study drug
|
TEAEs assessed and graded by CTCAE v5.0
|
Assessed from baseline to 30 days after last dose of study drug
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Elisabeth Oelmann, MD, PhD, NuCana plc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplasms
- Colorectal Neoplasms
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Fluorouracil
- Bevacizumab
- Leucovorin
- Irinotecan
Other Study ID Numbers
- NuTide:323
- 2022-001459-17 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Neoplasms
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
NuCana plcCompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States, France, United Kingdom
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
The Queen Elizabeth HospitalNovartis; AmgenCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalAustralia
-
Novartis PharmaceuticalsCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
ProgenaBiomeRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Carcinoma | Colorectal Adenocarcinoma | Colorectal SarcomaUnited States
-
Pawel KalinskiNational Cancer Institute (NCI)CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
Jeremy MeyerUniversity Hospital, Geneva; Hôpital Fribourgeois; Spital Biel, SwitzerlandNot yet recruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma | Colorectal Adenocarcinoma | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Neoplasms, Benign
-
Bristol-Myers SquibbNovartisActive, not recruitingColorectal Cancer | Colorectal Neoplasm | Colorectal Tumors | Colorectal CarcinomaItaly, United States, Canada, Spain, Argentina, Australia, Belgium, Chile, Czechia, Germany
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Disorders | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Adenomatous Polyp | Colorectal Cancer Stage I | Colorectal Adenoma... and other conditionsUnited States, Italy, China, Spain, Japan
Clinical Trials on Fosifloxuridine Nafalbenamide
-
NuCana plcRecruitingMelanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Neoplasm Malignant | Pleural... and other conditionsUnited Kingdom